Eric Easom, Chief Executive Officer at AN2 Therapeutics, Inc. (ANTX), sold 65,273 shares at $15.67 ($1.0M) on 2022-11-03, disclosed to the SEC on 2022-11-07.
Open-market sale of $1.0M ANTX by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.67 | 11,082 | $174K | 16.8% |
| 2 | $15.67 | 11,082 | $174K | 16.8% |
| 3 | $16.02 | 3,083 | $49K | 4.8% |
| 4 | $15.80 | 8,828 | $139K | 13.5% |
| 5 | $15.80 | 8,828 | $139K | 13.5% |
| 6 | $15.90 | 10,167 |
| $162K |
| 15.6% |
| 7 | $15.90 | 10,167 | $162K | 15.6% |
| 8 | $16.72 | 2,036 | $34K | 3.3% |
| Total | $15.83 avg | 65,273 | $1.0M | 100% |
| Filing → |
| ANTX | SELL | 2024-01-04 | $112K | — | Filing → |
| ANTX | BUY | 2023-05-15 | $54K | — | Filing → |
| ANTX | SELL | 2022-11-14 | $136K | — | Filing → |